Dacetuzumab

Drug Profile

Dacetuzumab

Alternative Names: huS2C6; PRO 64553; RG 3636; S2C6 monoclonal antibody; SGN 14; SGN-40

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Aug 2011 Discontinued - Phase-I for Multiple myeloma in European Union (IV)
  • 05 Aug 2011 Discontinued - Phase-I for Multiple myeloma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top